The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond
The career journey from molecular cancer biology through GMP manufacturing and regulatory science into health policy, the evolving regulatory landscape for cell and gene therapies in Singapore and the Asia‑Pacific region, the role of regulatory reliance frameworks in broadening equitable patient access, and the transformative potential of AI are discussed.